Company Profile
Spero Therapeutics Stock Price, News & Analysis
- Ticker:
- SPRO
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.27 USD (+0.79%)
Close
Last updated: August 6, 2026
164M USD
Market cap
Why the stock is moving
The latest company update was “Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)”. SPRO changed 0.79% and closed at $1.27 on Aug 6, 2026, indicating a relatively limited closing-price reaction to this company update.
Company overview
Business overview
Spero Therapeutics is an anti-infective company focused on bacterial infections and novel antibiotics. Its story is centered on addressing drug-resistant pathogens and difficult infection settings.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Spero sits in specialty biopharma.
Business Model Characteristics
The company depends on clinical data, regulatory steps, and the commercial opportunity in serious anti-infective markets.
Position Within the Biotechnology Landscape
Spero is a high-risk anti-infective name whose valuation is tied to pipeline and regulatory milestones.
Future catalysts
Spero Therapeutics’s catalysts are tebipenem HBr and any regulatory or partnering step that keeps the oral-carbapenem story alive. The company needs a cleaner development path to re-rate the name.
Recent news
- 01
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Source: Spero Therapeutics
- 02
- 03
Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer
Source: Spero Therapeutics
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Spero Therapeutics (SPRO)?
Spero Therapeutics (SPRO) most recently closed at 1.27 USD, a +0.79% move versus the previous session.
What is the market cap of Spero Therapeutics (SPRO)?
Spero Therapeutics currently has a market capitalization of 164M USD on BioPharmSignal.
What does Spero Therapeutics do?
Spero Therapeutics is an anti-infective company focused on bacterial infections and novel antibiotics. Its story is centered on addressing drug-resistant pathogens and difficult infection settings.
On which exchange is SPRO stock listed?
Spero Therapeutics (SPRO) is associated with NASDAQ, United States, Biopharma.
What is Spero?
Spero Therapeutics’s catalysts are tebipenem HBr and any regulatory or partnering step that keeps the oral-carbapenem story alive.
Which conditions is Spero Therapeutics targeting with Spero?
Spero Therapeutics’s catalysts are tebipenem HBr and any regulatory or partnering step that keeps the oral-carbapenem story alive.
How does Spero Therapeutics describe recent progress with Spero?
Spero Therapeutics’s catalysts are tebipenem HBr and any regulatory or partnering step that keeps the oral-carbapenem story alive.
What is Therapeutics?
Spero Therapeutics is an anti-infective company focused on bacterial infections and novel antibiotics.